Endocrine pituitary tumors arise from adenohypophyseal cells. Their classification has
evolved over the years supported by continuing improvements of numerous technologies …

The signal transduction events that orchestrate cellular activities required for angiogenesis
remain incompletely understood. We and others recently described that proangiogenic …

Pituitary tumors are amongst the most common intracranial neoplasms and are generally
benign. However, some pituitary tumors exhibit clinically aggressive behavior that is …

Context Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …

Abstract Cullin 4A (CUL4A) encodes a core subunit of an E3 ubiquitin ligase that targets
proteins for ubiquitin-mediated degradation, and aberrant expression of the CUL4A is found …

Pituitary tumors, the most frequent intracranial tumors, are historically considered benign.
However, various pieces of clinical evidence and recent advances in pathological and …

Although some pituitary adenomas may have an aggressive behavior, the vast majority are
benign. There are still controversies about predictive factors regarding the biological …

Pituitary adenomas (PAs) are adenohypophysial neoplasms, representing~ 10–15% of all
intracranial tumors, which are found to occur in almost 20% of the general population (1, 2) …

Abstract O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for
temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas …

Most prolactin-secreting pituitary adenomas demonstrate slow growth and are effectively
managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with …